ReWalk Robotics (LFWD) Set to Announce Earnings on Wednesday

ReWalk Robotics (NASDAQ:LFWD) will release its earnings data before the market opens on Wednesday, May 15th. Analysts expect ReWalk Robotics to post earnings of ($0.70) per share for the quarter. ReWalk Robotics has set its FY 2024 guidance at EPS and its Q1 2024 guidance at EPS.

ReWalk Robotics (NASDAQ:LFWD) last posted its quarterly earnings results on Tuesday, February 27th. The company reported ($0.35) EPS for the quarter, beating the consensus estimate of ($0.91) by $0.56. ReWalk Robotics had a negative net margin of 159.76% and a negative return on equity of 28.19%. The business had revenue of $6.88 million during the quarter, compared to analyst estimates of $7.20 million. On average, analysts expect ReWalk Robotics to post $-2 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

ReWalk Robotics Trading Down 0.6 %

NASDAQ LFWD opened at $4.82 on Wednesday. The company has a market capitalization of $40.97 million, a P/E ratio of -1.68 and a beta of 2.06. ReWalk Robotics has a 52-week low of $3.90 and a 52-week high of $9.10. The company’s 50 day simple moving average is $5.14.

Wall Street Analyst Weigh In

Separately, HC Wainwright reaffirmed a “buy” rating and set a $9.00 target price on shares of ReWalk Robotics in a research report on Monday, April 15th.

About ReWalk Robotics

ReWalk Robotics Ltd., a medical device company, designs, develops, and commercializes technologies that enable mobility and wellness in rehabilitation and daily life for individuals with physical and neurological conditions in the United States, Europe, the Asia-Pacific, and internationally. It offers ReWalk personal exoskeleton and rehabilitation exoskeleton devices; ReStore, a soft exo-suit intended for use in the rehabilitation of individuals with lower limb disability due to stroke; AlterG Anti-Gravity System for use in physical and neurological rehabilitation and athletic training; MyoCycle devices; and ReBoot, a personal soft exo-suit for home and community use by individuals post-stroke.